Duke logo

Accelerated Adaptive Radiation Therapy for NSCLC (ADAPT) (Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether giving radiation treatment in combination with chemotherapy in slightly higher daily doses over a shorter period of time could improve how lung cancer responds to treatment and improve overall progression free survival.

What is the Condition Being Studied?

Non-small cell lung cancer for which surgery is not an option

Who Can Participate in the Study?

Adults with unresectable stage II, IIIA, & IIIB non-small cell lung cancer who have not yet received chemotherapy or radiation for their disease.

Age Group
Adults

What is Involved?

If you choose to join this study:
You will receive standard of care chemotherapy with radiation therapy for about 5 weeks.
At the end of week 4 of radiation you will have a PET-CT scan to see if you are responding to treatment.

If you have a complete response, you will complete radiation therapy at 5 weeks

If you have residual disease on the PET-CT you may be eligible for an extra week of radiation therapy.

You may receive consolidation chemotherapy and/or immunotherapy 4-8 weeks after radiation therapy at the discretion of your treating medical oncologist.

Study Details

Full Title
Phase II Study of Accelerated and Adaptive Radiation Therapy for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Radiation Oncologist
Protocol Number
IRB:PRO00083154
NCT:NCT03128008
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698